Clinical Trial Update: A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC [Phase 2]

View source ↗

Summary

Phase II trial of BAY73-4506 in previously untreated metastatic or unresectable renal cell carcinoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• BAY73-4506 (BAY-73-4506)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: COMPLETED | Results posted: 2012-11-28